According to the company, the GelVac nasal powder platform brings distinct benefits to the vaccine products and patients. It is preservative-free, adjuvant-free and can stabilize vaccines at room temperature for a long period of time.
The vaccine requires no cold chain and allows needle-free administration, making it particularly well suited for influenza pandemic preparedness, as well as controlling the seasonal influenza. Besides the pandemic influenza (H5N1), the GelVac platform is also suitable for other vaccines, including the seasonal flu, the company said.
DelSite has also said that it has terminated manufacturing operations at its Irving, Texas facility. Continuation of non-manufacturing domestic operations and manufacturing at its Costa Rican plant is contingent on new funding.
Robert Schnitzius, acting president and CEO of DelSite, said: The company continues to seek outside funding and partnership for this and other powder development projects, including the seasonal influenza, human papillomavirus and typhoid vaccines. The survival of the company and initiation date of the clinical trial is contingent on when the company can raise sufficient funds to continue operations and initiate the trial. A contract research organization has been retained and dosing patient can begin within one month after securing adequate funding.